Elevage Medical Technologies has promoted Michael Wasserman, Ph.D., from Chief Operating Officer to Chief Executive Officer, effective immediately. The company announced the leadership change on October 12, 2026, as it continues supporting the development and growth of innovative medical technology businesses.
Wasserman brings more than 30 years of healthcare experience spanning scientific research, entrepreneurship, executive leadership and investment. Before joining Elevage, he served as Managing Partner at Maverix Private Equity and spent 17 years at H.I.G. Capital as a Managing Director within its BioHealth platform. Throughout his career, he has worked with management teams and medical technology companies across research and development, product development, commercialization, financing and corporate strategy.
In his new role, Wasserman will lead Elevage’s efforts to help medical technology companies navigate critical stages of growth. The company provides capital, technical expertise, regulatory support and operational guidance to businesses developing technologies intended to improve patient outcomes and quality of life.
Wasserman said the company would continue partnering with management teams and providing the resources needed to bring promising technologies to more patients. Elevage Chairman Jim Momtazee also recognized Wasserman’s contribution to the company’s development since its inception, expressing confidence in his leadership as the business continues to expand.
Read More: Kelly Pugh Appoints Ventra Health as SVP of Marketing
Established by Patient Square Capital, Elevage works with medical technology companies at stages ranging from advanced clinical development to commercial acceleration. Its model combines financial investment with operational and technical support, helping companies address the challenges involved in bringing differentiated technologies to market.
The appointment comes as medical technology companies face the complex task of translating scientific advances into commercially viable products. Beyond technical innovation, these businesses must navigate regulatory requirements, product development, financing and market adoption.
Wasserman’s experience across investment and healthcare technology positions him to guide Elevage through these challenges while maintaining its existing strategy and commitment to its partner companies. His appointment underscores the importance of combining scientific innovation with business expertise to help promising medical technologies reach wider markets.
